Trials / Completed
CompletedNCT01114230
A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M8F Monotherapy in Subjects With Advanced Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this dose escalation study is to examine the safety and pharmacokinetics (PK) of AGS-16M8F administered in subjects with advanced renal cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGS-16M8F | IV |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2010-05-03
- Last updated
- 2012-12-12
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01114230. Inclusion in this directory is not an endorsement.